JP2005535687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535687A5 JP2005535687A5 JP2004525349A JP2004525349A JP2005535687A5 JP 2005535687 A5 JP2005535687 A5 JP 2005535687A5 JP 2004525349 A JP2004525349 A JP 2004525349A JP 2004525349 A JP2004525349 A JP 2004525349A JP 2005535687 A5 JP2005535687 A5 JP 2005535687A5
- Authority
- JP
- Japan
- Prior art keywords
- tds
- phase
- rotigotine
- hydrophilic
- emulsify
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02016860A EP1386605A1 (en) | 2002-07-30 | 2002-07-30 | Improved transdermal delivery system for the administration of rotigotine |
| EP02016860.5 | 2002-07-30 | ||
| PCT/EP2003/008320 WO2004012730A1 (en) | 2002-07-30 | 2003-07-28 | Improved transdermal delivery system for the administration of rotigotine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011133638A Division JP5564469B2 (ja) | 2002-07-30 | 2011-06-15 | ロチゴチン投与のための改善された経皮送達系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005535687A JP2005535687A (ja) | 2005-11-24 |
| JP2005535687A5 true JP2005535687A5 (https=) | 2006-06-08 |
| JP4837916B2 JP4837916B2 (ja) | 2011-12-14 |
Family
ID=30011090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004525349A Expired - Lifetime JP4837916B2 (ja) | 2002-07-30 | 2003-07-28 | ロチゴチン投与のための改善された経皮送達系 |
| JP2011133638A Expired - Lifetime JP5564469B2 (ja) | 2002-07-30 | 2011-06-15 | ロチゴチン投与のための改善された経皮送達系 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011133638A Expired - Lifetime JP5564469B2 (ja) | 2002-07-30 | 2011-06-15 | ロチゴチン投与のための改善された経皮送達系 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1386605A1 (https=) |
| JP (2) | JP4837916B2 (https=) |
| KR (1) | KR101016838B1 (https=) |
| CN (2) | CN101953819A (https=) |
| AT (1) | ATE322263T1 (https=) |
| AU (1) | AU2003258539B2 (https=) |
| BR (1) | BR0313091A (https=) |
| CA (1) | CA2491366A1 (https=) |
| DE (1) | DE60304477T2 (https=) |
| DK (1) | DK1524975T3 (https=) |
| ES (1) | ES2256780T3 (https=) |
| IL (1) | IL165918A0 (https=) |
| MX (1) | MXPA05000350A (https=) |
| NO (1) | NO333297B1 (https=) |
| PL (1) | PL217079B1 (https=) |
| PT (1) | PT1524975E (https=) |
| SI (1) | SI1524975T1 (https=) |
| WO (1) | WO2004012730A1 (https=) |
| ZA (1) | ZA200500252B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
| EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE10361259A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| JP2008514376A (ja) * | 2004-09-29 | 2008-05-08 | シュウォーツ ファーマ インコーポレイテッド | パーキンソン病のための経皮治療システム |
| US7353034B2 (en) | 2005-04-04 | 2008-04-01 | X One, Inc. | Location sharing and tracking using mobile phones or other wireless devices |
| AU2009302853B2 (en) * | 2008-10-06 | 2014-09-11 | Mylan Technologies, Inc. | Amorphous rotigotine transdermal system |
| DE102008060203A1 (de) | 2008-12-07 | 2010-06-10 | Dietrich Wilhelm Schacht | Wirkstoffstabilisierende flächenförmige Vorrichtung |
| EP2201941A1 (de) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
| LT3257504T (lt) * | 2009-12-22 | 2024-08-26 | UCB Biopharma SRL | Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui |
| ES2608782T3 (es) | 2010-04-30 | 2017-04-17 | Teikoku Pharma Usa, Inc. | Composiciones transdérmicas de propinilaminoindano |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
| DE102011119043A1 (de) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TDS) mit Rotigotin |
| DE102011090178A1 (de) | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
| MX2015000049A (es) * | 2012-07-05 | 2015-04-08 | Sk Chemicals Co Ltd | Preparacion absorbible transdermicamente que contiene rotigotina. |
| AU2013338243B2 (en) | 2012-11-02 | 2016-09-29 | Teikoku Seiyaku Co., Ltd. | Propynylaminoindan transdermal compositions |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| JP2016135744A (ja) * | 2013-05-08 | 2016-07-28 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
| US20160199316A1 (en) | 2013-06-14 | 2016-07-14 | Tesa Labtec Gmbh | Three-layer transdermal therapy system (tts) |
| WO2014198422A1 (de) | 2013-06-14 | 2014-12-18 | Tesa Labtec Gmbh | Transdermales therapiesystem (tts) mit rotigotin |
| JP6726096B2 (ja) | 2013-07-03 | 2020-07-22 | エルテーエス ローマン テラピー−システメ アーゲー | 電子部品を有する経皮治療システム |
| CA2948219C (en) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| CN106456566B (zh) * | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
| US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| KR102364378B1 (ko) * | 2014-05-21 | 2022-02-16 | 에스케이케미칼 주식회사 | 안정성을 향상시킨 로티고틴 함유 경피흡수제제 |
| CN104382850B (zh) * | 2014-10-17 | 2017-12-22 | 烟台大学 | 一种罗替戈汀微乳及微乳凝胶 |
| WO2019234662A1 (en) * | 2018-06-07 | 2019-12-12 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing rotigotine |
| ES2966170T3 (es) | 2020-01-24 | 2024-04-18 | Luye Pharma Switzerland Ag | Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| DE19814083C2 (de) * | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE19940238A1 (de) * | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
| ATE246919T1 (de) * | 2001-05-08 | 2003-08-15 | Sanol Arznei Schwarz Gmbh | Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson |
| EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
| EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
-
2002
- 2002-07-30 EP EP02016860A patent/EP1386605A1/en not_active Withdrawn
-
2003
- 2003-07-28 CA CA002491366A patent/CA2491366A1/en not_active Abandoned
- 2003-07-28 WO PCT/EP2003/008320 patent/WO2004012730A1/en not_active Ceased
- 2003-07-28 EP EP03766331A patent/EP1524975B9/en not_active Expired - Lifetime
- 2003-07-28 AU AU2003258539A patent/AU2003258539B2/en not_active Expired
- 2003-07-28 CN CN2010102984651A patent/CN101953819A/zh active Pending
- 2003-07-28 ES ES03766331T patent/ES2256780T3/es not_active Expired - Lifetime
- 2003-07-28 MX MXPA05000350A patent/MXPA05000350A/es active IP Right Grant
- 2003-07-28 BR BR0313091-6A patent/BR0313091A/pt not_active Application Discontinuation
- 2003-07-28 PT PT03766331T patent/PT1524975E/pt unknown
- 2003-07-28 JP JP2004525349A patent/JP4837916B2/ja not_active Expired - Lifetime
- 2003-07-28 DE DE60304477T patent/DE60304477T2/de not_active Expired - Lifetime
- 2003-07-28 KR KR1020057001233A patent/KR101016838B1/ko not_active Expired - Lifetime
- 2003-07-28 DK DK03766331T patent/DK1524975T3/da active
- 2003-07-28 PL PL374814A patent/PL217079B1/pl unknown
- 2003-07-28 CN CNA038184257A patent/CN1671375A/zh active Pending
- 2003-07-28 SI SI200330224T patent/SI1524975T1/sl unknown
- 2003-07-28 AT AT03766331T patent/ATE322263T1/de active
-
2004
- 2004-12-22 IL IL16591804A patent/IL165918A0/xx unknown
-
2005
- 2005-01-11 ZA ZA2005/00252A patent/ZA200500252B/en unknown
- 2005-01-27 NO NO20050472A patent/NO333297B1/no not_active IP Right Cessation
-
2011
- 2011-06-15 JP JP2011133638A patent/JP5564469B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535687A5 (https=) | ||
| Wong et al. | Recent advancement of medical patch for transdermal drug delivery | |
| KR101016838B1 (ko) | 로티고틴 투여를 위한 향상된 경피 송달 시스템 | |
| TWI435737B (zh) | 經皮遞送醫藥化合物的方法及其組成物 | |
| JP2005535686A5 (https=) | ||
| JP5069402B2 (ja) | フェンタニル懸濁液をベースにしたシリコーン系粘着剤製剤及びフェンタニルを経皮送達するための装置 | |
| US8246980B2 (en) | Transdermal delivery system | |
| JP2015083569A (ja) | 安定化された経皮薬物送達システム | |
| CN102548546A (zh) | 用于施用芬太尼或其类似物的透皮治疗系统 | |
| JP2008507495A (ja) | 活性本体の経皮送達用デバイス | |
| Hadgraft et al. | Passive transdermal drug delivery systems: recent considerations and advances | |
| KR101016914B1 (ko) | 향상된 경피 송달 시스템 | |
| KR20050099537A (ko) | 활성 물질의 투과를 촉진시키기 위한 가열 용도에 적합한경피 치료 시스템, 및 이의 용도 | |
| KR20160106181A (ko) | 피부 투과 촉진 조성물, 경피 투여 제제 및 첩부 제제 | |
| Shokri et al. | The effect of pore-formers and plasticizers on the release kinetic of diltiazem hydrochloride from the controlled porosity osmotic pumps | |
| KR20200046461A (ko) | 비결정 로티고틴 함유 조성물 및 이의 제조 방법 | |
| HK1083459A (en) | Improved transdermal delivery system for the administration of rotigotine | |
| HK1083458B (en) | Improved transdermal delivery system | |
| HK1062650A (en) | Improved transdermal delivery system for the administration of rotigotine |